Cargando…

Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics

The novel coronavirus pneumonia (COVID-19) is a highly infectious acute respiratory disease caused by Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2) (Prec Clin Med 2020;3:9–13, Lancet 2020;395:497–506, N. Engl J Med 2020a;382:1199–207, Nature 2020;579:270–3). SARS-CoV-2 surveilla...

Descripción completa

Detalles Bibliográficos
Autores principales: Berber, Burak, Aydin, Cihan, Kocabas, Fatih, Guney-Esken, Gulen, Yilancioglu, Kaan, Karadag-Alpaslan, Medine, Caliseki, Mehmet, Yuce, Melek, Demir, Sevda, Tastan, Cihan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734466/
https://www.ncbi.nlm.nih.gov/pubmed/33318646
http://dx.doi.org/10.1038/s41434-020-00209-7
_version_ 1783622476515770368
author Berber, Burak
Aydin, Cihan
Kocabas, Fatih
Guney-Esken, Gulen
Yilancioglu, Kaan
Karadag-Alpaslan, Medine
Caliseki, Mehmet
Yuce, Melek
Demir, Sevda
Tastan, Cihan
author_facet Berber, Burak
Aydin, Cihan
Kocabas, Fatih
Guney-Esken, Gulen
Yilancioglu, Kaan
Karadag-Alpaslan, Medine
Caliseki, Mehmet
Yuce, Melek
Demir, Sevda
Tastan, Cihan
author_sort Berber, Burak
collection PubMed
description The novel coronavirus pneumonia (COVID-19) is a highly infectious acute respiratory disease caused by Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2) (Prec Clin Med 2020;3:9–13, Lancet 2020;395:497–506, N. Engl J Med 2020a;382:1199–207, Nature 2020;579:270–3). SARS-CoV-2 surveillance is essential to controlling widespread transmission. However, there are several challenges associated with the diagnostic of the COVID-19 during the current outbreak (Liu and Li (2019), Nature 2020;579:265–9, N. Engl J Med 2020;382:727–33). Firstly, the high number of cases overwhelms diagnostic test capacity and proposes the need for a rapid solution for sample processing (Science 2018;360:444–8). Secondly, SARS-CoV-2 is closely related to other important coronavirus species and subspecies, so detection assays can give false-positive results if they are not efficiently specific to SARS-CoV-2. Thirdly, patients with suspected SARS-CoV-2 infection sometimes have a different respiratory viral infection or co-infections with SARS-CoV-2 and other respiratory viruses (MedRxiv 2020a;1–18). Confirmation of the COVID-19 is performed mainly by virus isolation followed by RT-PCR and sequencing (N. Engl J Med 2020;382:727–33, MedRxiv 2020a, Turkish J Biol 2020;44:192–202). The emergence and outbreak of the novel coronavirus highlighted the urgent need for new therapeutic technologies that are fast, precise, stable, easy to manufacture, and target-specific for surveillance and treatment. Molecular biology tools that include gene-editing approaches such as CRISPR-Cas12/13-based SHERLOCK, DETECTR, CARVER and PAC-MAN, antisense oligonucleotides, antisense peptide nucleic acids, ribozymes, aptamers, and RNAi silencing approaches produced with cutting-edge scientific advances compared to conventional diagnostic or treatment methods could be vital in COVID-19 and other future outbreaks. Thus, in this review, we will discuss potent the molecular biology approaches that can revolutionize diagnostic of viral infections and therapies to fight COVID-19 in a highly specific, stable, and efficient way.
format Online
Article
Text
id pubmed-7734466
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-77344662020-12-14 Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics Berber, Burak Aydin, Cihan Kocabas, Fatih Guney-Esken, Gulen Yilancioglu, Kaan Karadag-Alpaslan, Medine Caliseki, Mehmet Yuce, Melek Demir, Sevda Tastan, Cihan Gene Ther Review Article The novel coronavirus pneumonia (COVID-19) is a highly infectious acute respiratory disease caused by Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2) (Prec Clin Med 2020;3:9–13, Lancet 2020;395:497–506, N. Engl J Med 2020a;382:1199–207, Nature 2020;579:270–3). SARS-CoV-2 surveillance is essential to controlling widespread transmission. However, there are several challenges associated with the diagnostic of the COVID-19 during the current outbreak (Liu and Li (2019), Nature 2020;579:265–9, N. Engl J Med 2020;382:727–33). Firstly, the high number of cases overwhelms diagnostic test capacity and proposes the need for a rapid solution for sample processing (Science 2018;360:444–8). Secondly, SARS-CoV-2 is closely related to other important coronavirus species and subspecies, so detection assays can give false-positive results if they are not efficiently specific to SARS-CoV-2. Thirdly, patients with suspected SARS-CoV-2 infection sometimes have a different respiratory viral infection or co-infections with SARS-CoV-2 and other respiratory viruses (MedRxiv 2020a;1–18). Confirmation of the COVID-19 is performed mainly by virus isolation followed by RT-PCR and sequencing (N. Engl J Med 2020;382:727–33, MedRxiv 2020a, Turkish J Biol 2020;44:192–202). The emergence and outbreak of the novel coronavirus highlighted the urgent need for new therapeutic technologies that are fast, precise, stable, easy to manufacture, and target-specific for surveillance and treatment. Molecular biology tools that include gene-editing approaches such as CRISPR-Cas12/13-based SHERLOCK, DETECTR, CARVER and PAC-MAN, antisense oligonucleotides, antisense peptide nucleic acids, ribozymes, aptamers, and RNAi silencing approaches produced with cutting-edge scientific advances compared to conventional diagnostic or treatment methods could be vital in COVID-19 and other future outbreaks. Thus, in this review, we will discuss potent the molecular biology approaches that can revolutionize diagnostic of viral infections and therapies to fight COVID-19 in a highly specific, stable, and efficient way. Nature Publishing Group UK 2020-12-14 2021 /pmc/articles/PMC7734466/ /pubmed/33318646 http://dx.doi.org/10.1038/s41434-020-00209-7 Text en © The Author(s), under exclusive licence to Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Berber, Burak
Aydin, Cihan
Kocabas, Fatih
Guney-Esken, Gulen
Yilancioglu, Kaan
Karadag-Alpaslan, Medine
Caliseki, Mehmet
Yuce, Melek
Demir, Sevda
Tastan, Cihan
Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
title Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
title_full Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
title_fullStr Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
title_full_unstemmed Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
title_short Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
title_sort gene editing and rnai approaches for covid-19 diagnostics and therapeutics
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734466/
https://www.ncbi.nlm.nih.gov/pubmed/33318646
http://dx.doi.org/10.1038/s41434-020-00209-7
work_keys_str_mv AT berberburak geneeditingandrnaiapproachesforcovid19diagnosticsandtherapeutics
AT aydincihan geneeditingandrnaiapproachesforcovid19diagnosticsandtherapeutics
AT kocabasfatih geneeditingandrnaiapproachesforcovid19diagnosticsandtherapeutics
AT guneyeskengulen geneeditingandrnaiapproachesforcovid19diagnosticsandtherapeutics
AT yilancioglukaan geneeditingandrnaiapproachesforcovid19diagnosticsandtherapeutics
AT karadagalpaslanmedine geneeditingandrnaiapproachesforcovid19diagnosticsandtherapeutics
AT calisekimehmet geneeditingandrnaiapproachesforcovid19diagnosticsandtherapeutics
AT yucemelek geneeditingandrnaiapproachesforcovid19diagnosticsandtherapeutics
AT demirsevda geneeditingandrnaiapproachesforcovid19diagnosticsandtherapeutics
AT tastancihan geneeditingandrnaiapproachesforcovid19diagnosticsandtherapeutics